LncRNA GAS5 inhibits the remodeling of the tumor microenvironment by binding to miR-93-5p, thereby suppressing the development of osteosarcoma Authors: Tianbo Zhu, Xiaokang Zhu, You Zhou, Wenyao Chen, Wei Huang, Yafeng Lv, Xiangyong Que, Yi Li, Qingsong Tian, Mireadeli Abulimiti, Xinzhi Li Published: 2026 ABSTRACT AbstractThe inflammatory tumor immune microenvironment is being increasingly recognized as a key driver of osteosarcoma (OS) progression; however, the molecular mechanisms linking long noncoding RNAs (lncRNAs) to inflammasome signaling in OS remain poorly understood. In this study, we investigated the role of growth arrest-specific transcript 5 (GAS5) in regulating inflammatory remodeling and tumor development. We found that GAS5 expression was significantly decreased in osteosarcoma cells, whereas miR-93-5p expression was upregulated, indicating a potential inverse regulatory relationship. Mechanistically, GAS5 functioned as a competing endogenous RNA for miR-93-5p, thereby alleviating miR-93-5p–mediated downregulation of the E3 ubiquitin ligase TRIM31. Restoration of TRIM31 expression promoted NLRP3 protein turnover and attenuated inflammasome activation, as evidenced by reduced cleaved caspase-1, GSDMD-N, and IL-18 secretion. Functionally, GAS5 overexpression suppressed inflammatory cytokine production and limited protumorigenic inflammatory remodeling, ultimately inhibiting osteosarcoma cell progression. Collectively, our findings reveal a novel GAS5/miR-93-5p/TRIM31/NLRP3 regulatory axis that connects lncRNA-mediated posttranscriptional control to inflammasome signaling in osteosarcoma, providing new mechanistic insight and a potential therapeutic framework for targeting inflammation-associated OS progression.Supplementary InformationThe online version contains supplementary material available at 10.1186/s13018-026-06852-x.Keywords: Osteosarcoma, GAS5, miR-93-5p, Long noncoding RNA Background Osteosarcoma (OS) is the most common primary malignant bone tumor and is characterized by aggressive local invasion and a strong likelihood of early metastasis [1]. Although its exact etiology remains unclear, OS occurs predominantly in children and adolescents [2, 3]. Advances in surgical techniques and systemic cancer therapies have improved survival in patients with OS [4, 5]. However, early metastatic spread and marked disease heterogeneity still result in unsatisfactory outcomes, and key issues related to OS progression and prognosis remain unresolved [6, 7]. Increasing evidence indicates that OS progression and therapeutic response are not dictated solely by tumor-intrinsic programs but are strongly shaped by the tumor immune microenvironment (TIME) [8, 9]. The TIME consists of heterogeneous immune and stromal cell populations whose composition and activation states can remodel inflammation and influence malignant behavior [10]. Inflammasomes are central inflammatory signaling platforms in both tumor and immune compartments, and among them, NLRP3 is among the most extensively characterized sensors that respond to diverse sterile danger signals (e.g., oxidative stress, ion flux, and damage-associated molecular patterns) [11]. By driving IL-1β/IL-18 maturation and gasdermin D–dependent pyroptosis, NLRP3 can reprogram local inflammatory tone and thereby alter TIME features [12–14]. However, how NLRP3-dependent inflammasome activity shapes the OS immune microenvironment to impact OS progression has not been systematically elucidated. Growth arrest-specific transcript 5 (GAS5) is a long noncoding RNA (lncRNA) that is generally considered a tumor suppressor in OS, mainly through miRNA-mediated regulation of proliferation, invasion, and drug response. More broadly, small noncoding RNAs, particularly miRNAs, have emerged as important regulators and potential therapeutic targets in a wide range of musculoskeletal disorders, including tendon injury, osteoarthritis, and osteoporosis, highlighting the relevance of ncRNA-centered regulatory networks in orthopedic diseases [15–17]. Recent reviews have further suggested that RNA-based strategies, including siRNA- and circRNA-oriented approaches, are being explored for inflammatory and metabolic skeletal disorders, supporting the translational potential of ncRNA-targeted interventions in musculoskeletal medicine [18–20]. Nevertheless, whether GAS5 contributes to OS progression by modulating inflammatory signaling or TIME-related phenotypes remains largely unexplored, and its potential mechanistic link to inflammasome pathways has not been defined. Here, we propose and validate a previously unrecognized GAS5-centered regulatory circuit connecting lncRNA control to inflammasome signaling in OS. We tested the hypothesis that GAS5 functions as a competing endogenous RNA for miR-93-5p, thereby alleviating miR-93-5p–mediated repression of the E3 ligase TRIM31, which promotes NLRP3 protein turnover and constrains inflammasome-dependent outputs. This hypothesis is also biologically plausible in light of emerging evidence showing that specific miRNAs and lncRNA–miRNA regulatory axes can modulate inflammation, apoptosis, and tissue remodeling in orthopedic disorders [21, 22]. Similarly, lncRNA-associated ceRNA networks have been reported to influence fracture repair and inflammatory orthopedic diseases, further supporting the pathogenic relevance of lncRNA–miRNA interaction networks [23, 24]. By integrating clinical expression analyses with cell-based functional assays, molecular interaction studies (RIP and WT/MUT dual-luciferase reporters), and inflammasome/pyroptosis readouts (GSDMD-N, cleaved caspase-1, and IL-18), we revealed a GAS5/miR-93-5p/TRIM31/NLRP3 axis and demonstrated its cytokine-linked, microenvironment-relevant inflammatory consequences in osteosarcoma. Methods Patients In this study, bone and soft tissue samples from osteosarcoma tumors and corresponding adjacent nontumor tissues were collected from patients who underwent surgical resection at Renhe Hospital of China Three Gorges University from January 2024 to December 2025. Additionally, frozen sections from previous surgical resections were also included. All diagnoses were confirmed through histopathological examination. Paired sampling was used to reduce differences among patients, and all tissue samples were immediately frozen in liquid nitrogen and stored at − 80 °C until RNA extraction. The study protocol was approved by the Ethics Committee of Renhe Hospital of China Three Gorges University, and written informed consent was obtained in accordance with the Declaration of Helsinki. Cell culture The human osteosarcoma cell lines MG-63 and U2OS and the normal human osteoblastic cell line hFOB1.19 were purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). MG-63 and U2OS cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM; Gibco, USA) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin at 37 °C in a humidified incubator with 5% CO2. The hFOB1.19 cell line was cultured in DMEM/Ham’s F-12 medium supplemented with 10% FBS and 400 mg/mL geneticin at 34 °C in 5% CO2. When the cells reached 80–90% confluence, they were passaged using standard trypsinization procedures. Plasmids The sequences of the miRNA mimics and inhibitors used in this study are listed below: miR-Ctrl, 5′-UUCUCCGAACGUGUCACGUTT-3′; miR-Ctrl, 5′-UUCUCCGAACGUGUCACGUTT-3′; miR-93-5p, 5′-CAAAGUGCUGUUCGUGCAGGUAG-3′; miR-93-5p, 5′-CAAAGUGCUGUUCGUGCAGGUAG-3′; miR-Ctrl-inhibitor, 5′-CAGUACUUUUGUGUAGUACAA-3′; miR-Ctrl-inhibitor, 5′-CAGUACUUUUGUGUAGUACAA-3′; miR-93-5p-inhibitor, 5′-CUACCUGCACGAACAGCACUUUG-3′; miR-93-5p-inhibitor, 5′-CUACCUGCACGAACAGCACUUUG-3′; The sequence of human GAS5 (ENST00000651080.1) was obtained from the UCSC Genome Browser. The sequence of human TRIM31 (Gene ID: 11074) was obtained from the NCBI Reference Sequence database. The siRNA sequences used for knockdown of TRIM31 were as follows: 5′-GGACCACAAAUCCCAUAAUTT-3′; 5′-GGACCACAAAUCCCAUAAUTT-3′; 5′-AUUAUGGGAUUUGUGGUCCTT-3′. 5′-AUUAUGGGAUUUGUGGUCCTT-3′. si-NC: 5′-UUCUCCGAACGUGUCACGUTT-3′; si-NC: 5′-UUCUCCGAACGUGUCACGUTT-3′; 5′-ACGUGACACGUUCGGAGAATT-3′. 5′-ACGUGACACGUUCGGAGAATT-3′. Plasmids for the overexpression or knockdown of GAS5 and TRIM31 were inserted into the pcDNA3.1(+) vector (Invitrogen) according to the above sequences by Sangon Biotech (Shanghai, China). A human ubiquitin E3 ligase–inactive mutant of TRIM31 (C53A/C56A) was generated following the methods published in a previous report and was referred to as TRIM31-Mut [25]. Tumor–macrophage coculture To better model tumor–immune interactions, THP-1 cells were differentiated into macrophages using phorbol 12-myristate 13-acetate (PMA) and then cocultured with osteosarcoma cells using a Transwell system (0.4 μm pore size) to allow paracrine signaling without direct contact. Osteosarcoma cells with the indicated genetic manipulations (GAS5/miR-93-5p/TRIM31/NLRP3 axis) were seeded in the lower chamber, and THP-1–derived macrophages were placed in the upper insert. After coculture under basal conditions or with LPS challenge, cytokines in the conditioned medium were measured, and macrophage polarization-associated markers (e.g., CD86/iNOS for M1 and CD206/ARG1 for M2) were assessed by RT–qPCR and/or flow cytometry, as indicated. Bioinformatic analysis The human osteosarcoma-related microarray dataset GSE28423 (containing 19 osteosarcoma cell lines and 4 normal bone samples as controls) was downloaded from the Gene Expression Omnibus (GEO) database. To identify potential miRNA targets of GAS5, we first predicted miRNAs that could bind to GAS5 using the miRcode database. We then used the online tool “Venny 2.1” (https://bioinfogp.cnb.csic.es/tools/venny/) to generate a Venn diagram showing the overlapping miRcode-predicted GAS5-targeting miRNAs and miRNAs present in the GSE28423 dataset. The overlapping miRNAs were considered potential binding miRNAs of GAS5. RNA isolation and real-time PCR Total RNA from clinical specimens and cells was extracted using a total RNA kit (Yeasen, Shanghai, China; Catalog number 19221ES50). RNA purity was assessed by measuring the OD260/OD280 ratio, and samples whose ratios were between 1.9 and 2.0 were reverse transcribed. cDNA was synthesized using a reverse transcription kit (Vazyme, Nanjing, China; catalog no. R223-01). For miRNA determination, total RNA was reverse transcribed using a miRNA 1st synthesis kit (Vazyme, Nanjing, China; Catalog number MR201). Next, real-time PCR was conducted by using a SYBR Green Master Mix Kit (Yeasen, Shanghai, China; catalog number 11201ES08). To normalize gene expression, β-actin was used as an internal control for mRNAs and lncRNAs, and U6 was used as an internal control for miRNAs. Relative gene expression was calculated using the 2^-ΔΔCt method. The primers used in this study are listed in Table S1. Western blotting analysis Cells were lysed in Triton X-100 lysis buffer supplemented with protease inhibitor cocktail (1:100 dilution) for 30 min on ice and then centrifuged at 12,000 rpm for 10 min at 4 °C. The supernatants were mixed with 6 × SDS loading buffer, boiled for 10 min and stored at − 80 °C. Subsequently, 50–100 µg of cellular extract was separated on 10% SDS–polyacrylamide gels, transferred to polyvinylidene difluoride membranes, blocked with 5% nonfat dry milk (Bio-Rad, Hercules, CA, USA; catalog number 1706404) in Tris-buffered saline with Tween (TBST) for 1 h at room temperature, and then incubated with primary antibodies overnight at 4 °C according to the manufacturer’s instructions. After being washed three times with TBST, the membranes were incubated with a horseradish peroxidase-conjugated secondary antibody (Proteintech, Wuhan, China; catalog number SA00001-1; diluted 1:3000) for 1 h at room temperature and detected using an enhanced chemiluminescence detection reagent (Yeasen, Shanghai, China; catalog number 36208ES60). The immunoblots were visualized using an Amey Imager 600RGB and quantified with ImageJ software. Enzyme-linked immunosorbent assay (ELISA) The levels of IL-6 (catalog number KE00139), TNF-α (catalog number KE00154), IL-1β (catalog number KE00021), and IL-18 (catalog number as provided by the manufacturer) were quantified using ELISA kits (Proteintech, Wuhan, China) according to the manufacturer’s instructions. For secreted cytokines, culture supernatants were collected and clarified by centrifugation prior to the assay. Cell counting kit-8 (CCK-8) assay Cells in the logarithmic growth phase were seeded in 96-well plates (100 µL culture medium containing 1 × 104 cells per well) and incubated for 24, 48, or 72 h under different conditions. Next, 10 µL of CCK-8 reagent (MedChemExpress, Monmouth Junction, NJ, USA; catalog number HY-K0301) was added to each well, followed by incubation for 4–5 h. The absorbance of each sample was measured at 450 nm using a microplate reader (Thermo Fisher Scientific, Waltham, MA, USA). Cell proliferation under different treatment conditions was evaluated on the basis of the absorbance values at 450 nm. Each experiment was performed in triplicate, and the results were averaged. Luciferase reporter assay Dual-luciferase reporter assays were performed to validate the sequence-specific interactions between (i) GAS5 and miR-93-5p and (ii) miR-93-5p and the TRIM31 3′ UTR. In brief, reporter plasmids containing a wild-type (WT) GAS5 fragment encompassing the predicted miR-93-5p binding site (GAS5-WT) and a corresponding mutant construct (GAS5-MUT) with seed-matching nucleotides substituted were generated. Similarly, TRIM31-3′UTR-WT and TRIM31-3′UTR-MUT reporters were generated by site-directed mutagenesis at the predicted miR-93-5p binding site. U2OS cells were cotransfected with the indicated miRNA mimics/inhibitors and WT/MUT reporters (pmirGLO; Promega) using Transfectamine™ 5000. After 36 h, the firefly and Renilla luciferase activities were measured using the Dual-Luciferase Reporter Assay System (Promega), and firefly activity was normalized to Renilla activity. All experiments were performed independently with at least three biological replicates. Reagents and antibodies The antibodies used for Western blotting were as follows: anti-β-actin (Proteintech; 66009-1-Ig; 1:10,000), anti-NLRP3 (Proteintech; 68102-1-Ig; 1:3000), anti-GSDMD-N (Abcam; ab215203; 1:1000), anti-TRIM31 (Abcam; ab67785; 1:1000), and anti-cleaved caspase-1 p20/caspase-1 (commercial source and dilution as provided by the manufacturer). LPS (MedChemExpress; HY-D1056) was used for inflammatory stimulation as described above. Cells were stimulated with LPS for 3 h for cytokine induction assays unless otherwise stated. LPS (MedChemExpress, Monmouth Junction, NJ, USA; catalog number HY-D1056) was used at a concentration of 100 ng/mL to stimulate the cells for 3 h. RNA immunoprecipitation (RIP) To determine the potential interaction between GAS5 and miR-93-5p, a Magna RIP™ RNA-Binding Protein Immunoprecipitation Kit (#17-700; Millipore) was used. The cell lysates were incubated with an anti-Ago2 antibody (Proteintech; 67934-1-Ig) to capture RISC-associated RNAs, with normal IgG (Proteintech; B900620) processed in parallel as the negative control. After immunoprecipitation, RNA was purified using TRIzol and analyzed by RT–qPCR. Enrichment was calculated relative to input and compared between Ago2-IP and IgG-IP to confirm specificity. Statistics All experiments were performed with ≥ 3 independent biological replicates unless otherwise stated. For RT–qPCR, each biological replicate was measured with three technical replicates. The data are presented as the mean ± SD. Normality was assessed using the Shapiro–Wilk test to guide the use of parametric (two-tailed Student’s t test for two-group comparisons; one-way ANOVA with Tukey’s post hoc test for multiple groups) or nonparametric tests (Mann–Whitney U test). For analyses involving multiple simultaneous hypotheses in bioinformatic datasets, P values were adjusted using the Benjamini–Hochberg false discovery rate (FDR) procedure, and significance was determined on the basis of adjusted q values where applicable. Statistical analyses were performed using GraphPad Prism and R (version and packages specified in the bioinformatics analysis section). Significance notation: ns, not significant; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Results GAS5 interacted with miR-93-5p in osteosarcoma cells LncRNAs play crucial roles in OS development, of which GAS5 is a typical representative. We first validated GAS5 expression in paired clinical specimens (n = 30 osteosarcoma tumors and matched adjacent tissues; Fig. 1a), which revealed that GAS5 expression was significantly downregulated in tumors. Similarly, compared with that in hFOB1.19 cells, GAS5 expression in U2OS and MG-63 osteosarcoma cell lines was reduced (Figs. 1b and S1a). GAS5 interacts with miR-93-5p in osteosarcoma and is downregulated in clinical samples. a RT–qPCR analysis of GAS5 expression in 30 paired osteosarcoma tissues and matched adjacent tissues (n = 30 pairs). b RT–qPCR analysis of GAS5 in hFOB1.19 and U2OS cells. c Venn diagram showing overlapping miRNAs between miRcode-predicted GAS5-binding miRNAs and miRNAs present in GSE28423. d Differential expression of miR-93 in the GSE28423 cohort (osteosarcoma vs. normal controls). e RT–qPCR analysis of miR-93-5p after GAS5 overexpression or knockdown in U2OS and MG-63 cells. f RIP-qPCR results showing enrichment of GAS5 and miR-93-5p in Ago2 immunoprecipitates compared with IgG control. g and h WT/MUT dual-luciferase reporter assay validating sequence-specific binding between GAS5 and miR-93-5p. The data are presented as the means ± SDs of three independent experiments. Differences were considered to be statistically significant when * indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001, and **** indicates p < 0.0001 To further explore the role of GAS5 in OS development, we first downloaded the human osteosarcoma-associated microarray miRNA dataset, GSE28423 (which includes 19 osteosarcoma cell lines and 4 normal bone samples as controls), from the Gene Expression Omnibus (GEO). Venn diagrams were subsequently constructed to determine the overlapping miRNAs between potential GAS5 target miRNAs (obtained through miRcode) and miRNAs in GSE28423 (Fig. 1c). Venn analysis revealed eight candidate GAS5-binding miRNAs. Among them, miR-93-5p was reported to be related to the immune microenvironment. Furthermore, we compared the expression levels of miR-93-5p in tumor tissues and corresponding normal tissues in the GSE28423 cohort. The results revealed that the expression of miR-93-5p was significantly increased in tumor tissues (Fig. 1d). To explore the association between GAS5 and miR-93-5p, we overexpressed or knocked down GAS5 in U2OS and MG-63 cells and then evaluated the expression of miR-93-5p. GAS5 inhibited the expression of miR-93-5p in U2OS and MG-63 cells (Fig. 1e). Additionally, using RNA immunoprecipitation with an anti-Ago2 antibody, we detected that the enrichment of GAS5 and miR-93-5p in the Ago2 complex was significantly greater in U2OS cells than in IgG control cells. These results indicate that GAS5 and miR-93-5p interact with one another in osteosarcoma cells (Fig. 1f). To provide direct, site-specific binding evidence beyond RIP enrichment, we performed a WT/MUT dual-luciferase reporter assay. Cotransfection of the miR-93-5p mimic significantly altered the luciferase activity of the GAS5-WT reporter, whereas this effect was markedly attenuated in the GAS5-MUT reporter, supporting a sequence-specific interaction between GAS5 and miR-93-5p (Fig. 1g and h). These results suggest that GAS5 is downregulated in osteosarcoma and decreases miR-93-5p expression through direct interaction, thereby contributing to the inhibition of osteosarcoma progression. Knockdown of miR-93-5p inhibited osteosarcoma development and the LPS-induced inflammatory response To further investigate the role of miR-93-5p in the development of osteosarcoma and its impact on the tumor microenvironment, we knocked down miR-93-5p in osteosarcoma cells (U2OS and MG-63) (Fig. 2a). Since the expression of miR-93-5p was increased in osteosarcoma cells, we knocked down miR-93-5p to highlight the more obvious changes in the experiments. We observed that knockdown of miR-93-5p expression significantly reduced the proliferation of U2OS and MG-63 cells (Fig. 2b). Knockdown of miR-93-5p inhibits osteosarcoma cell proliferation and attenuates LPS-induced cytokine secretion. a U2OS and MG-63 cells were transfected with a miR-93-5p inhibitor or the corresponding negative control. Total RNA was extracted, and miR-93-5p knockdown efficiency was validated by RT–qPCR. b After the indicated transfections, U2OS and MG-63 cells were replated into 96-well plates, and cell viability/proliferation was monitored at the indicated time points using a CCK-8 assay. c Following miR-93-5p knockdown (or control), U2OS cells were stimulated with LPS (100 ng/mL) for 3 h. Culture supernatants were collected, and the levels of IL-6, TNF-α, and IL-1β were quantified by ELISA. d MG-63 cells were treated in parallel (miR-93-5p inhibitor vs. control, followed by treatment with 100 ng/mL LPS for 3 h). The supernatants were harvested, and the levels of IL-6, TNF-α, and IL-1β were measured by ELISA. The data are presented as the means ± SDs of three independent experiments. Differences were considered to be statistically significant when * indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001, and **** indicates p < 0.0001 To further investigate the effect of miR-93-5p on the tumor microenvironment, as shown in Fig. S3, we treated miR-93-5p knockdown U2OS and MG-63 cells with LPS and then measured the secretion levels of the inflammatory cytokines IL-6, TNF-α and IL-1β by ELISA. After LPS stimulation, the levels of IL-6, TNF-α and IL-1β in U2OS cells significantly increased, but the cytokine levels in U2OS cells significantly decreased after knockdown of miR-93-5p (Fig. 2c). The same results were obtained in MG-63 cells (Fig. 2d). These results indicate that knockdown of miR-93-5p can inhibit the proliferation of osteosarcoma cells and reduce the secretion of associated cytokines, thereby affecting the tumor microenvironment. Overexpression of miR-93-5p partially abolished the effects of GAS5 on OS development and inflammation To determine the role of the interaction between GAS5 and miR-93-5p in the pathogenesis of OS, we overexpressed GAS5 and miR-93-5p in U2OS cells and MG-63 cells. The data revealed that overexpression of miR-93-5p significantly abrogated the inhibition of U2OS and MG-63 cell proliferation induced by GAS5 overexpression (Fig. 3a). miR-93-5p overexpression partially abolishes GAS5-mediated antiproliferative and anti-inflammatory effects. a U2OS and MG-63 cells were transfected to overexpress GAS5, with or without cotransfection of a miR-93-5p mimic (and matched controls). Cells were then subjected to CCK-8 assays at the indicated time points to evaluate the effect of miR-93-5p on the inhibition of GAS5-mediated proliferation. b After GAS5 overexpression with or without the miR-93-5p mimic, U2OS cells were stimulated with LPS (100 ng/mL) for 3 h. Supernatants were collected, and IL-6, TNF-α, and IL-1β levels were quantified by ELISA. c MG-63 cells were treated in parallel (GAS5 overexpression vector ± miR-93-5p mimic, followed by treatment with 100 ng/mL LPS for 3 h). The supernatants were harvested, and the levels of IL-6, TNF-α, and IL-1β were measured by ELISA. d For the tumor‒macrophage interaction experiment, conditioned medium was generated by culturing osteosarcoma cells with the corresponding treatments with macrophages, and markers related to macrophage polarization (such as CD86 and CD206) were evaluated under the set conditions of tumor cells. The data are presented as the means ± SDs of three independent experiments. Differences were considered to be statistically significant when * indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001, and **** indicates p < 0.0001 LPS has been shown to regulate key processes such as angiogenesis, inflammation, and the tumor microenvironment, all of which contribute to osteosarcoma progression [26]. We further explored the influence of the interaction between GAS5 and miR-93-5p on the tumor microenvironment, especially the inflammatory factors responsible for recruiting immune cells. We stimulated U2OS and MG-63 cells overexpressing GAS5 and miR-93-5p with LPS and then measured the secretion levels of the inflammatory factors IL-6, TNF-α, and IL-1β by ELISA. The results revealed that the levels of IL-6, TNF-α, and IL-1β in U2OS cells significantly increased after LPS stimulation, whereas GAS5 overexpression significantly inhibited the expression of inflammatory factors. However, the coexpression of GAS5 and miR-93-5p restored the levels of inflammatory factors in U2OS cells (Fig. 3b). The same results were obtained in MG-63 cells (Fig. 3c). These results indicate that in osteosarcoma, miR-93-5p counteracts the tumor suppressive function of GAS5 by abrogating the inhibition of cell proliferation and the reduction in inflammatory factor secretion caused by the overexpression of GAS5. To assess how soluble factors released from differently treated U2OS cells regulate macrophage polarization, U2OS cells were subjected to treatment with miR-Ctrl, miR-Ctrl + LPS, GAS5 + miR-Ctrl + LPS, or GAS5 + miR-93-5p + LPS, and the conditioned media were collected and applied to differentiated macrophages. Macrophages exposed to conditioned medium (CM) from miR-Ctrl-treated U2OS cells were predominantly distributed in the Q3 (CD86⁻CD206⁻) population, indicating limited basal polarization. CM from miR-Ctrl + LPS-treated cells markedly increased the CD86⁺CD206⁻ (Q1) population, suggesting enhanced CD86 induction and a shift toward an M1-like phenotype. Compared with the CM from the miR-Ctrl + LPS group, the CM from the GAS5 + miR-Ctrl + LPS-treated cells reduced the Q1 population, indicating that GAS5 attenuated CM-driven M1-like polarization/activation. Notably, compared with CM from the GAS5 + miR-Ctrl + LPS group, CM from the GAS5 + miR-93-5p + LPS-treated cells increased the Q1 population again, suggesting that miR-93-5p partially reversed the inhibitory effect of GAS5 (Fig. 3d). miR-93-5p modulates NLRP3 inflammasome activation and pyroptosis in osteosarcoma cells To further investigate the effects of GAS5 and miR-93-5p on inflammatory signal transduction, we focused on IL-1β and IL-18, whose maturation is tightly regulated by inflammasome activation. We first examined the effect of miR-93-5p on the secretion of IL-18 in osteosarcoma cells. The results showed that miR-93-5p significantly promoted the secretion of IL-18 (Fig. 4a). To further confirm inflammasome activation, we also evaluated the activation of caspase-1. We observed that miR-93-5p significantly promoted the cleavage of caspase-1 (Fig. 4b). To further explore the activation of the inflammasome in osteosarcoma, we compared the NLRP3 protein content in osteosarcoma cells with that in hFOB1.19 cells and found that the content of NLRP3 in osteosarcoma cells increased (Fig. 4c). Further inhibition of miR-93-5p expression in osteosarcoma cells resulted in a reduction in NLRP3 and GSDMD-N levels under LPS stimulation (Fig. 4d and e). These results suggest that miR-93-5p promotes the activation of NLRP3-related inflammasomes in osteosarcoma cells. miR-93-5p modulates NLRP3 inflammasome activation and pyroptosis-related outputs in osteosarcoma cells. a and b U2OS/MG-63 cells were transfected with a miR-93-5p inhibitor (or control) and then challenged with LPS. The supernatant was collected, and IL-18 levels were measured. Additionally, the cell lysate was subjected to immunoblotting to detect cleaved caspase-1 (p20) and assess the activation of the inflammasome and the related signaling pathways involved in cell pyroptosis. c Whole-cell lysates from hFOB1.19, U2OS, and MG-63 cells were prepared and analyzed by Western blotting to compare the basal protein levels of NLRP3 and GSDMD-N. d and e U2OS/MG-63 cells were transfected with a miR-93-5p inhibitor (or control) and then challenged with LPS. Subsequently, the cell lysates were subjected to immunoblotting to detect NLRP3 and GSDMD-N expression, thereby evaluating the activation of the inflammasome and the related signaling pathways involved in cell pyroptosis. The data are presented as the means ± SDs of three independent experiments. Differences were considered to be statistically significant when * indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001, and **** indicates p < 0.0001 TRIM31 is a direct target of miR-93-5p and regulates NLRP3 protein expression Since the NLRP3 protein is a key initiating factor for pyroptosis, we investigated how miR-93-5p increases NLRP3 protein levels. miR-93-5p did not significantly affect NLRP3 mRNA expression (Fig. S2), suggesting that posttranscriptional regulation occurred. Because miRNAs typically repress targets, we hypothesized that miR-93-5p targets negative regulators of NLRP3 protein stability, including several reported E3 ligases. RT–qPCR screening revealed that TRIM31 expression showed the most prominent change upon miR-93-5p treatment (Fig. 5a). These data suggest that TRIM31 is a target of miR-93-5p. Consistent with our expectations, TRIM31 overexpression reduced NLRP3 expression, leading to the inhibition of pyroptosis in U2OS and MG-63 cells (Fig. 5b). Further experiments revealed that overexpression of miR-93-5p inhibited TRIM31 expression (Fig. 5c). To validate direct targeting, we mapped the predicted miR-93-5p binding site within the TRIM31 3′ UTR and constructed TRIM31-3′UTR-WT and TRIM31-3′UTR-MUT luciferase reporters. Dual-luciferase assays revealed that the miR-93-5p mimic significantly suppressed WT reporter activity, whereas suppression was substantially reduced in the MUT reporter (Fig. 5d). These results indicate that TRIM31 is a direct target of miR-93-5p and that miR-93-5p is responsible for regulating the expression of the NLRP3 protein. TRIM31 is a direct target of miR-93-5p and mediates NLRP3 protein regulation. a After miR-93-5p modulation in osteosarcoma cells, total RNA was extracted, and RT–qPCR was performed to screen reported NLRP3-related E3 ligases (MARCH7, FBXL2, PARKIN, TRIM31, CHIP, and UBR5). b Cells were transfected to overexpress TRIM31; whole-cell lysates were collected and analyzed by Western blotting for NLRP3 and pyroptosis-related proteins to assess whether TRIM31 alters NLRP3-associated signaling at the protein level. c After the modulation of miR-93-5p expression, the abundance of the TRIM31 protein was evaluated by Western blotting to confirm that miR-93-5p regulates TRIM31 expression. d A dual-luciferase reporter assay was performed by cotransfecting a miR-93-5p mimic (or control) with reporters carrying the wild-type (WT) or mutant (MUT) TRIM31 3′UTR. Relative luciferase activity was quantified to validate the direct targeting of the TRIM31 3′UTR by miR-93-5p. The data are presented as the means ± SDs of three independent experiments. Differences were considered to be statistically significant when * indicates p < 0.05, ** indicates p < 0.01, *** indicates p < 0.001, and **** indicates p < 0.0001 Proinflammatory remodeling of the osteosarcoma immune microenvironment: group and paired evidence To evaluate whether this cell-intrinsic mechanism aligns with immune context in patient samples, we next analyzed public transcriptomes. In the public transcriptome dataset, we first constructed an inflammatory composite score (sum of CD8 T cells, NK cells, M1 macrophages, neutrophils, and DCs minus M2 macrophages) on the basis of the quanTIseq estimation of immune cell proportions in the GSE39055 cohort. After the samples were divided into two groups, Inflam-High and Inflam-Low using the median score, we found that M1 macrophages and NK cells were significantly enriched/ in the Inflam-High group; M2 macrophages were enriched in the Inflam-Low group, and the composite score was significantly greater in the Inflam-High group, suggesting that the microenvironment shifted toward an inflammatory/effective phenotype. This pattern is consistent with the classical activation (M1 polarization) mediated by the proinflammatory cytokine network (TNF, IL-1, and IL-6) and is opposite to the immunosuppressive/tissue repair phenotype (M2) (Fig. 6a). To validate the above population trends at the individual level, we conducted a paired analysis of biopsy and postoperative resection samples from the same patient in GSE39057. The results revealed that in most paired samples, the proportion of M1 macrophages was increased in the resection samples compared to the biopsy samples, while the proportion of M2 macrophages decreased; the inflammatory composite score generally increased; the number of neutrophils tended to decrease overall but with individual variations; and the number of NK cells increased in some cases (Fig. 6b). Although the number of paired samples was small (n ≈ 5), the changes in M1/M2/inflammatory scores in the paired samples were consistent with the population stratification results in GSE39055, suggesting that changes in treatment/disease stage may accompany the remodeling of the immune microenvironment from inhibitory to inflammatory. Public transcriptomic analyses suggest an inflammatory-leaning osteosarcoma immune context but remain correlative. a Public transcriptomes (GSE39055) were analyzed using quanTIseq to estimate immune cell proportions. An inflammatory composite score was calculated (as defined in the Methods section), and the samples were stratified into Inflam-High vs. Inflam-Low according to the median split to compare immune composition and inflammatory score differences between groups. b A paired analysis was conducted in GSE39057 by comparing biopsy versus resection samples from the same patients; each line denotes a matched pair from one patient. The results were interpreted as correlative and not causal Discussion Osteosarcoma is a highly aggressive malignancy in children and young adults, and metastatic disease remains the major cause of death. Inflammation and inflammasome signaling have been increasingly implicated in osteosarcoma biology, yet the upstream noncoding RNA programs that connect tumor-intrinsic regulation to inflammasome activation and inflammatory outputs remain incompletely understood. Our findings are in line with broader orthopedic literature showing that ncRNA dysregulation not only is mechanistically important but also may have diagnostic and therapeutic implications across musculoskeletal diseases [27]. Here, we report a GAS5/miR-93-5p/TRIM31/NLRP3 regulatory axis in which loss of the tumor-suppressive lncRNA GAS5 activated miR-93-5p, reduced the expression of the E3 ligase TRIM31, and thereby increased NLRP3 protein accumulation. A key conceptual issue in cancer biology is that NLRP3 signaling functions as a double-edged sword. On the one hand, persistent or dysregulated NLRP3 activation can sustain chronic, tumor-supportive inflammation by promoting IL-1β and IL-18 maturation, recruiting myeloid-derived suppressor cells (MDSCs), and fostering an immunosuppressive milieu that facilitates tumor growth and metastasis. Indeed, in several solid tumors, elevated IL-1β signaling has been associated with enhanced angiogenesis, stromal remodeling, and resistance to therapy, illustrating how inflammasome-driven cytokines may reinforce protumorigenic circuits [28]. On the other hand, acute or appropriately regulated inflammasome activation can induce gasdermin D-mediated pyroptosis, resulting in lytic tumor cell death and the release of damage-associated molecular patterns (DAMPs), which may promote dendritic cell activation and cytotoxic T-cell priming [29]. For example, in certain preclinical models, pharmacologic or genetic induction of pyroptosis has been shown to convert “cold” tumors into more immunogenic, T-cell–inflamed states. These contrasting observations underscore that NLRP3 activity cannot be simplistically classified as either beneficial or detrimental in cancer. In our experimental system, GAS5 overexpression consistently suppressed LPS-induced inflammatory cytokine secretion and reduced the expression of NLRP3-associated readouts, including cleaved caspase-1 and GSDMD-N, whereas the effects of miR-93-5p were the opposite. These findings support a tumor-suppressive role of GAS5 and a proinflammatory role of miR-93-5p under defined in vitro conditions. Functionally, the attenuation of IL-18 release and pyroptosis-related signaling in GAS5-overexpressing cells aligns with reduced inflammatory amplification, suggesting that the GAS5/miR-93-5p/TRIM31 axis constrains excessive inflammasome activation at the tumor cell level. However, the net biological impact of NLRP3 activation in patients is likely highly context dependent. Variables such as the intrinsic state of tumor cells (e.g., genetic background and metabolic profile), the nature and duration of stimuli (sterile stress versus microbial ligands), and the composition and activation status of infiltrating immune cells may fundamentally alter outcomes. For instance, inflammasome activation within tumor cells may primarily influence cytokine gradients, whereas activation within myeloid cells in the TIME could shape antigen presentation or immunosuppression in distinct ways. Thus, while our data provide mechanistic evidence that GAS5 modulates NLRP3 signaling and inflammatory outputs in controlled cellular models, they do not definitively establish how this pathway remodels the in vivo immune microenvironment. Rather, our findings offer a conceptual and molecular framework that invites further investigation in immunocompetent and clinically relevant models to determine when and how targeting this axis might tip the balance toward antitumor immunity instead of tumor-promoting inflammation. Although our experiments were primarily conducted without tumor cells, the microenvironmental relevance is supported by downstream paracrine outputs (cytokine secretion) and by a tumor–macrophage coculture model showing that modulation of the GAS5/miR-93-5p axis in tumor cells is associated with changes in macrophage polarization markers. In parallel, public transcriptomic analyses (GSE39055/GSE39057) suggest that osteosarcoma samples with an inflammatory-leaning immune context exhibit increased effector-associated signatures; however, these deconvolution-based patterns are correlated, and causality between GAS5 expression, inflammasome activation, and immune cell composition cannot be established. Our study has several important limitations. First, our functional assays were performed mainly in two osteosarcoma cell lines (U2OS and MG-63), and LPS was employed as an exogenous inflammatory trigger; this model does not fully recapitulate the spatial and temporal complexity of the in vivo TIME. Second, while we expanded tissue validation to 30 paired samples, larger multicenter cohorts will be needed to assess clinical associations and interpatient heterogeneity more definitively. This point is particularly relevant because, in other musculoskeletal disorders, the clinical utility of ncRNAs as biomarkers requires larger validation cohorts and more standardized evaluation frameworks [27, 30]. Third, complete corresponding clinical information was lacking for the 30 newly collected samples. Fourth, we were unable to include in vivo experiments (e.g., xenograft or orthotopic models), which limits translational interpretation. Finally, other inflammasome sensors and additional E3 ligases may contribute to different contexts and were not comprehensively ruled out. Future work should validate this axis in patient-derived materials and in vivo models and leverage single-cell and spatial approaches to resolve the cellular sources and spatial niches of inflammasome activation. Mechanistically, identifying alternative inflammasome sensors and compensatory ubiquitin ligases, as well as testing pharmacologic or genetic modulation of the GAS5/miR-93-5p/TRIM31/NLRP3 axis in combination with chemotherapy or immunotherapy, will be important next steps. Future translational work may also benefit from lessons learned in other orthopedic conditions, where targeting disease-associated miRNAs or broader ncRNA circuits has already been proposed as a therapeutic strategy [15, 18, 22]. Overall, our findings provide a mechanistic framework linking a lncRNA–miRNA–E3 ligase circuit to NLRP3-associated inflammatory outputs in osteosarcoma, but therapeutic implications remain to be generated until in vivo efficacy and safety are established. Conclusions This study shows that lncRNA GAS5 suppresses osteosarcoma progression by sponging miR-93-5p, upregulating Trim31, and inhibiting NLRP3 inflammasome activation, thereby reducing the inflammatory microenvironment, tumor growth, and invasion. These findings highlight the GAS5/miR-93-5p/Trim31/NLRP3 axis as an important regulatory pathway in osteosarcoma. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 2 Supplementary Material 3 Acknowledgements Not applicable. Abbreviations Osteosarcoma Growth arrest transcript 5 Tumor immune microenvironment Tumor-associated macrophages Myeloid-derived suppressor cells Cancer-associated fibroblasts Matrix metalloproteinases Author contributions TZ, XZ and YZ performed the experiments. TZ designed the experiments and analyzed the data. TZ and XL wrote the manuscript. WC, WH, YL, XQ, YL, QT, and MA contributed to manuscript preparation. TZ and XL supervised the project. All the authors read and approved the final manuscript. Funding This research was supported by grants from the Hubei Provincial Department of Education Scientific Research Program Young Talents Project (Grant No. Z2024303) and the Open Foundation of Hubei Province Key Laboratory of Tumor Microenvironment and Immunotherapy (Grant No. 2024KZL02). The funders were not involved in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Data availability All the data generated or analyzed during this study are included in this published article. Declarations Ethics approval and consent to participate The Institutional Review Board approved the protocol for this study (No. RHLL-2025–01), and written informed consent was obtained from all participants or their legal guardians in accordance with the Declaration of Helsinki. Consent for publication Written informed consent for publication was not needed, as this study did not include any identifiable personal or clinical details of the participants. Competing interests The authors declare no competing interests. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Tianbo Zhu, Email: 284105831@qq.com. Xinzhi Li, Email: lixpj@163.com. References Associated Data Supplementary Materials Supplementary Material 1 Supplementary Material 2 Supplementary Material 3 Data Availability Statement All the data generated or analyzed during this study are included in this published article.